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Abstract 
 
Objective: Osteoarthritis (OA) is a global clinical challenge for which no effective 
disease modifying agents currently exist. Herein we identify protease-activated receptor-2 
(PAR-2) as a novel pathogenic mechanism and potential therapeutic target in OA.  
Methods: Experimental OA was induced in wild-type and PAR-2 deficient mice by 
sectioning the medial menisco-tibial ligament (MMTL), leading to development of a mild 
arthropathy. Cartilage degradation and increased subchondral bone formation were 
assessed as indicators of OA pathology. 
Results: Four weeks following MMTL section, cartilage erosion and increased 
subchondral bone formation was evident in wild type mice but substantially reduced in 
PAR-2 deficient mice. Crucially, therapeutic inhibition of PAR-2 in wild type mice, 
using either a PAR-2 antagonist or a monoclonal antibody targeting the protease cleavage 
site of PAR-2, was also equally effective at reducing OA progression in vivo. PAR-2 was 
upregulated in chondrocytes of wild-type but not sham-operated mice. Wild type mice 
showed further joint degradation eight weeks following induction of OA, but PAR-2 
deficient mice were still protected.  
Conclusions: The substantial protection from pathology afforded by PAR-2 deficiency 
following induction of OA provides proof of concept that PAR-2 has a key role in OA 
and suggests this receptor as a potential therapeutic target. 
 
  
Osteoarthritis (OA) is a chronic disabling condition currently affecting millions globally 1 
with radiological evidence of OA in approximately 80% of the population aged over 65. 2 
OA is characterised by cartilage degradation and increased subchondral bone formation 
(osteosclerosis). Despite extensive pathophysiologic investigations, clinical management 
has not altered significantly and comprises administration of analgesics and non-steroidal 
anti-inflammatory agents and recourse upon joint failure to arthroplasty. No unifying 
pathogenetic model exists - suggested hypotheses encompass primary cartilage metabolic 
dysregulation, enthesial disease together with biomechanical dysregulation. Thus far, no 
critical checkpoint pathway has been identified that is essential for disease progression 
and which might by corollary represent a valid, disease-modifying OA therapeutic target. 
Protease-activated receptor-2 (PAR-2) is a G-protein coupled receptor whose ‘tethered’ 
ligand is activated by serine proteases. 3 PAR-2 is present in chondrocytes in cartilage 
from OA patients 4, and following its activation, matrix metalloproteases (MMPs) are 
generated. 5 However, these previous observations are associative and do not establish the 
role of PAR-2 in the pathogenesis of OA. We here sought direct evidence of a causal 
relationship between PAR-2 expression and cartilage and bone pathology in a murine 
model of OA. 
 
 
Methods 
 
Animals 
Experiments were performed on adult wild-type (PAR-2+/+) C57BL/6J mice (body weight 
25-30 g), housed in standard cages, with food and water available ad libitum, and 
maintained in a thermoneutral environment. PAR-2-deficient (PAR-2-/-) mice were 
genetically modified 6 and maintained under the same conditions. All procedures were 
performed in accordance United Kingdom Home Office regulations. 
 
Induction of experimental osteoarthritis 
Two previously described models of joint instability were employed. 7 The principal 
model used involved destabilisation of the medial meniscus by section of the medial 
menisco-tibial ligament (MMTL), which results in development of a mild arthropathy 
resembling human OA.7 A more severe model, involving  anterior cruciate ligament 
(ACL) transection, was induced in a smaller group of mice. 7 All surgical procedures 
were performed by the same investigator who was blinded to genotype or treatment. 
Following surgery, animals were left for 4 or 8 weeks and thereafter, knee joints were 
harvested for subsequent histological analysis. Knee joint diameter was measured weekly 
for a month following MMTL surgery in a small cohort of mice but no significant 
difference occurred over time (P=0.6, 1-way ANOVA, n = 6). As similar results were 
obtained with the ACL section model, no further such measurements were performed. 
  
Assessment of cartilage damage 
Histological analysis of progression and severity of cartilage damage was undertaken on 
harvested joints, involving decalcification by incubating knee joints in 4% 
paraformaldehyde solution followed by phosphate buffer and then in 10% EDTA solution 
at 4oC for 2 weeks.  Joints were embedded in paraffin wax and frontal sections (6μm) cut 
at 200μm intervals, followed by staining with Haematoxylin, Safranin-O/fast green. Ten 
sections from each mouse were graded using a validated scoring system, 7 from 0 
(normal) to 6 (>80% loss of cartilage) by two scorers blinded to the specimens, taking 
each quadrant of the joint separately and then summing scores. There was close 
agreement between scorers (intraclass correlation coefficient 0.97; 95% CI 0.95 to 0.98) 
with the mean difference in score being -0.05 (95% CI 0.01 to -0.11). 
 
Assessment of osteosclerosis 
From the sections obtained above, two were chosen at random, digitally captured 
(Olympus BX51, DP70, AnalySIS software) and stored for computerised planimetry 
analysis using QS Onscreen v 3.1.19, (E-quantities Ltd; http://www.e-quantities.com). 
Only two photomicrographs per mouse were required for planimetric analysis as 
osteosclerosis was relatively consistent across sections (coefficient of variation 2.1%). 
The area of the medial and lateral aspects of the tibial plateau were traced, from the 
epiphyseal plate to the lower zone of cartilage adjacent to subchondral bone. The tibial 
plateau region was selected as cartilage damage was maximal at medial aspect with the 
lateral region never appearing to be affected in MMTL-sectioned wild-type mice, and so 
could be used as an internal reference. Controls were also performed in sham-operated as 
well as naïve mice. Once the overall area on each side of the tibial plateau was 
determined, areas containing marrow were traced, summed and subtracted from the 
overall area on each side to yield the area occupied by bone. Comparisons were made by 
expressing as the percentage area occupied by bone in the medial tibial compared to the 
lateral region in order to normalise for animal size, since analysis of naïve mice showed 
the difference between these areas to be minimal (1.1 ± 3.4%, mean ± sem, n = 5). Scores 
were independently verified by another blinded assessor and there was good agreement 
between scorers (intraclass correlation coefficient 0.91; 95% CI 0.77 to 0.97) with the 
mean difference in score being 2.7% (95% CI 5.45 to -0.06). Osteosclerosis was not 
assessed in the ACL model as it was previously reported that bone erosion can penetrate 
to the epiphyseal plate. 7 
  
 
Immunohistochemistry 
Following decalcification, sections were deparaffinized, rehydrated and stained with the 
murine monoclonal antibody (mAb) SAM-11 (Santa Cruz Biotechnology, Santa Cruz, 
CA) at 1µg/ml using the Dako (Ely, UK) ARK (Animal Research Kit) Peroxidase. SAM-
11 is a highly specific mAb to human PAR-2 that binds the membrane-bound part of the 
receptor. Antigen–antibody complex was visualized utilizing diaminobenzidine (DAB) 
and counterstained with hematoxylin. The ARK was utilised to minimise reactivity of 
secondary anti-mouse antibody with endogenous immunoglobulin. 
 
Statistical analysis 
Data were tested for normality (Sigmastat 2.03, SPSS Inc) and expressed as mean ± sem 
with comparisons by one or two way ANOVA and multiple comparisons using 
Bonferroni correction. Non-normal data were transformed (square root) prior to statistical 
analysis and if normality was still not achieved, non-parametric methods were used. 
Agreement between scorers was assessed graphically using the Bland Altman plot 8 and 
expressed as the intraclass correlation coefficient.  
 
 
Results  
 
 
Four weeks following MMTL section, immunohistochemical analysis of cartilage 
revealed increased PAR-2 expression in superficial layer chondrocytes (Fig 1a), 
compared to sham-operated mice (Fig 1b). Having established enhanced expression of 
the PAR-2 pathway with plausible tissue distribution, pathology was compared in wild-
type mice (PAR-2+/+; n = 5) and PAR-2 deficient littermates (PAR-2-/-; n = 5), with sham-
operated wild-type mice (n = 4) serving as a negative control. Compared to sham-
operated mice (Fig 1d), PAR-2+/+ mice showed cartilage damage and increased 
subchondral bone formation (Fig 1e) whereas such changes were minimal in PAR-2-/- 
mice (Fig 1f). Such differences could not be attributed to an underlying difference in 
bone phenotype of PAR-2-/- mice as the appearance of the unoperated knee did not differ 
from wild-type littermates (Supplementary Fig 1). To address the therapeutic utility of 
PAR-2, operated mice (n = 6) were treated with SAM-11 antibody, which we previously 
demonstrated inhibits PAR-2 activation. 9 In a further group (n = 5), we utilised p520, a 
selective PAR-2 antagonist. 10 Consistent with data in the PAR-2 deficient animals, mice 
treated with SAM-11 (Fig 1g) or p520 showed significantly reduced OA pathology four 
weeks post-operatively (Fig 1 h, i).  
 
Two-way ANOVA revealed a significant difference in cartilage degradation between 
groups (P < 0.0001) and between regions (P < 0.0001).  PAR-2+/+ mice exhibited 
significantly greater cartilage degradation than sham-operated, PAR-2-/- mice, or wild-
type mice treated with p520 (Fig 1h). Similarly, operated mice receiving an isotype 
antibody developed substantially greater cartilage degradation than SAM-11-treated mice. 
Consistent with previous work, 7 cartilage damage only occurred at the medial aspects of 
the tibia and femur. Analysis of subchondral bone revealed differences between treatment 
groups (P = 0.006, 1-way ANOVA). PAR-2+/+ mice differentiated from sham-operated, 
PAR-2-/- mice, and wild-type recipients of p520 (Fig 1i). Consistent with this, mice 
receiving isotype control showed substantially greater osteosclerosis than SAM-11 
recipients. Cartilage damage and osteosclerosis scores were significantly correlated (r = 
0.7, P < 0.0001). Since genetic deficiency of PAR-2, or inhibition by two distinct routes, 
namely targeting the protease cleavage site with SAM-11 or directly by receptor 
antagonism, proved effective in preventing the development of experimental OA, we 
conclude that PAR-2 as a pivotal checkpoint in early progression of OA pathology. 
   
The longer term effects of PAR-2 biology were examined using PAR-2 deficient mice by 
extending the postoperative period to eight weeks. Compared to wild-type littermates 
(Fig 2a) cartilage damage was still significantly (P <0.0001, 2-way ANOVA, n = 7-8) 
lower in PAR-2-/- mice (Fig 2b, c) and once again the latter showed no evidence of 
increased subchondral bone formation, whereas PAR-2+/+ mice showed a significant 
increase compared to the 4 week model (Fig 2d). To further test our hypothesis, the more 
aggressive ACL transection model was investigated. PAR-2+/+ mice developed almost 
complete cartilage erosion, particularly at the medial femoral condyle (Fig 3a, c), 
whereas PAR-2-/- mice exhibited significantly (P < 0.0001, 2-way ANOVA, n = 7-8) 
lower levels of damage (Fig 3b, c).  
 
Discussion 
 
Our observations in PAR-2 deficient mice using both MMTL and ACL transection 
models provide powerful proof of concept for a key role of PAR-2 in joint degradation 
associated with OA, and furthermore demonstrate the therapeutic potential of PAR-2 
inhibition, which could have preventative clinical utility.  The mechanism by which 
PAR-2 promotes OA has yet to be clarified. PAR-2 provides for sensing by cells of the 
protease environment and allows them to subsequently respond.  For example, PAR-2 
regulates synovial release of pro-inflammatory cytokines including IL-1β, 11 which is in 
turn a potent chondrocyte catabolin. 12 Activation of PAR-2 leads to inhibition of 
osteoclast differentiation 13 and could alter the balance between bone formation and 
resorption and thereby contribute to osteosclerosis observed in PAR-2+/+ but not PAR-2-/- 
mice. However, whether PAR-2 has a direct or indirect effect on the bone phenotype and 
its hierarchical role in OA are areas for further investigation. Prior studies revealed that 
selective PAR-2 activation of chondrocytes derived from human OA cartilage leads to 
generation of MMP-1 and -13, 5 both of which are known to play a key role in 
degradation of aggrecan and collagens. Although the initiating event in the development 
of OA lesions remains unknown, our data suggest that PAR-2 is a crucial checkpoint that 
mediates the effect of biomechanical instability upon cartilage degradation and 
osteosclerosis. PAR-2 inhibitors could therefore provide a new direction in the 
development of disease modifying osteoarthritis drugs (DMOADs), which following 
disappointing results of trials with MMP inhibitors, biphosphonates and cytokine 
inhibition, 14 still remain elusive.  
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Figure Legends 
 
 
Fig 1.   PAR-2 absence or inhibition ameliorates OA pathology in the four week MMTL 
model. Immunohistochemistry of cartilage in the medial tibial aspect using SAM-
11 to detect PAR-2 shows increased surface expression in chondrocytes of the 
wild-type mouse following MMTL section (a), compared to a sham-operated 
animal (b), with isotype control (c). Bar indicates 50µm. Histological appearances 
of the medial aspect of the knee joint four weeks following sham-operation (d), or 
following MMTL section in either a wild-type (e) or PAR-2 deficient mouse (f), 
or wild-type mouse treated daily with SAM-11 (1µg i.p.) immediately prior to and 
after induction of OA (g). Arrowheads in (e) denote cartilage damage and * 
indicates osteosclerosis. Scale bar in panel f indicates 500µm and applies to all 
four photomicrographs. Cartilage degradation scores (h) for the medial tibial 
(MT), medial femoral (MF), lateral tibial (LT) and lateral femoral (LF) regions 
following MMTL section in PAR-2+/+ and PAR-2-/- mice, PAR-2+/+ mice treated 
with PAR-2 antagonist p520 (5mg i.p. daily), SAM-11 (1µg i.p. daily) or isotype 
(IgG2a) control antibody (ISO; 1µg i.p. daily), along with sham operated controls. 
Data are expressed as mean ± sem, n = 4 - 6. Analysis by one-way ANOVA with 
multiple comparisons using the Bonferroni correction, * = P < 0.05; ** = P < 
0.01; *** = P <0.001. † =  P< 0.005, Mann-Whitney rank sum test.  Percentage 
difference in bone area (i) comparing the medial and lateral tibial regions 
following MMTL transection in the above groups of mice along with a naïve 
control group. Analysis by one-way ANOVA with multiple comparisons using 
the Bonferroni correction, * = P < 0.05; ** = P < 0.02; *** = P < 0.01. § = P < 
0.001, t-test. NS = not significant, t-test.  
 
 
Fig 2.  PAR-2 deficiency still confers protection eight weeks following MMTL section. 
Examination of the medial tibial and femoral regions of the PAR-2+/+mouse (a) 
compared to its PAR-2-/- littermate (b) eight weeks following MMTL section 
shows continued protection in the latter. Scale bars indicate 500µm. This was 
confirmed for these two groups (n = 7 and 8 respectively) in terms of cartilage 
damage scores (c). ** = P < 0.01, *** = P < 0.001. Osteosclerosis, comparing % 
difference in bone area between the medial and lateral tibial areas, showed a 
significant increase in the eight week model (MMTL8) compared to 4 weeks 
(MMTL4) in PAR-2+/+ mice but no difference between the PAR-2-/- groups (d). * 
= P < 0.02, ** = P < 0.0001.  
 
 
Fig 3.   Eight weeks following ACL transection, substantial damage was evident in 
multiple areas of the knee in PAR-2+/+ (a), but less so in PAR-2-/- mice (b). Scale 
bar indicates 1000µm. Cartilage damage scores confirm the more extensive nature 
of damage in this model of arthritis, but there remain significant differences 
compared to PAR-2-/- mice (c). *** = P < 0.001, ** = P < 0.005, * = P < 0.05. 
 
Supplementary Fig 1. Comparison of the unoperated knee joint from the wild-type 
mouse (a) with its PAR-2-/- littermate (b) shows no apparent difference in 
cartilage or bone phenotype. Scale bars indicate 500µm. Medial tibial bone areas 
in (a) and (b) were 44.8% and 43.2%, respectively.  
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